 |
|
|
| |
Pharmacokinetics, Safety, and Tolerability of EDP-239,
a novel Hepatitis C NS5A inhibitor, in Healthy Volunteers
|
| |
| |
Reported by Jules Levin
ICAAC 2015 Sept 17-21 2015 San Diego, CA
Lijuan Jiang1, Xuemin Jiang2, Kiran Dole2, Kimberly Caliri1, Kenneth Tack1, Richard Colvin2, Yat Sun Or1
1 Enanta Pharmaceuticals Inc., Watertown MA; 2 Novartis Institutes for Biomedical Research, Cambridge, MA
|
| |
|
|
|
|
|
